Theradiag IMMUNO-TROL Quality Controls are unassayed non-kit controls. This means that the controls do not have values or reference ranges assigned by the manufacturer.
Webinar: Development of sensitive ADA assays using automated acid dissociation in Gyrolab Mixing CD 96
Measuring Anti-Drug-Antibody (ADA) levels is an important part of developing new biologics. The clinical implication of the presence of anti-drug-antibodies in treated patients may include allergic reactions, immune complex toxicity, autoimmune reactions and reduction of efficacy.
Meet HAL® S2225 – The World’s Most Advanced Pediatric Simulator. Registration now open.
The fully automated IdyllaTM EGFR Mutation Test delivers results in 2.5h for 51 mutations in exons 18–21 using only 1 FFPE tissue section from metastatic NSCLC.
LEF-1 and SOX-11 (MRQ-58) and – top IHC performers for your Lymphoma panel.
We are pleased to be launching the next edition of Cell Marque disease of the month. This is a continuation of a series of disease overviews where we will present commonly diagnosed disease groups and the relevant Cell Marque immunohistochemistry antibodies to assist in the disease diagnosis.
Take advantage of the modular design and tailor it to your ELISA and KINETIC assay application needs.
Tick borne diseases comprise a group of infections transmitted to humans by the bite of ticks infected with bacteria, viruses, or parasites. Tick borne diseases affecting humans include: Lyme disease, relapsing fever, Babesiosis, Anaplasmosis, Ehrlichiosis, Q fever, tick-borne encephalitis and spotted fever among others.
Osteoporosis is a medical condition in which the bones become fragile from loss of bone mass. Osteoporosis is caused by a disturbance in the normal turnover process of bone, typically as a result of hormonal changes, or deficiency of calcium or vitamin D. Consequently it leads to an increased risk of bone fractures.
Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the CE-IVD marking of its fully automated Idylla™ MSI Test which allows for fast and accurate information on a patient’s MSI status directly from a single sample of FFPE colorectal cancer tumor tissue. This CE-IVD launch is a key addition to Biocartis’ colorectal cancer (CRC) Idylla™ test menu as MSI detection is currently recommended for all patients with CRC.